An experimental norovirus vaccine has been found to lessen the main symptoms of the gastrointestinal infection by more than half, according to research presented this week at the IDWeek 2013 infectious diseases conference in San Francisco.

The investigational vaccine, which reportedly seems to be generally well tolerated and effective from the most typical strain from the RNA virus, has been discovered to lessen vomiting and/or diarrhea linked to the condition by 52 percent, according to lead author David I. Bernstein of Cincinnati Children’s Hospital Medical Center and his colleagues.

Currently, there isn\’t any treatment or remedy for norovirus, which is the leading reason for severe gastrointestinal infection in the US. It causes nearly 90 % of all epidemic non-bacterial outbreaks of gastroenteritis worldwide and may affect people of all ages. It is almost always transmitted by contaminated food or water, by person-to-person contact, or through aerosolization of the virus.

\”Significant outbreaks occur in health care facilities, childcare centers along with other places where individuals are in close quarters, including in the military and on luxury cruise ships,\” the Infectious Diseases Society of the usa (IDSA), sponsors of IDWeek 2013, said inside a statement. \”Each year, 19 to 21 million Americans C one out of 15 C are infected and as many as 800 die, according to the Cdc and Prevention (CDC). In addition, one recent evaluation reports the total cost from the disease in the usa is $5.5 billion annually.\”

Bernstein and his colleagues conducted a randomized, multi-center study featuring 98 individuals who consented to drinking water contaminated having a tremendous amount of the virus. Fifty of those participants were injected with the vaccine, and also the remaining 48 received a placebo injection. Neither group knew ahead of time which group had received the vaccine and which group hadn\’t.

Twenty-six people in the vaccine group (52 percent) were infected, as were 29 members (60 percent) of these in the placebo group. Among those who did not get the vaccine, which targeted the GI.1 and GII.4 genotypes of norovirus, 20 members (42 percent) suffered from mild, moderate or severe vomiting and/or diarrhea. In contrast, 10 (20 %) from the vaccine group experienced those symptoms C a discount of 52 percent.

\”Norovirus truly is a global issue and most if not everyone has experienced it to some degree. The results in our study are promising and our next thing would be to test this vaccine inside a real-world setting,\” said Dr. Bernstein.

\”If the vaccine is constantly on the prove as effective as our initial results indicate, it may be employed for specific populations or situations C in those in a higher risk of severe disease such as the elderly or at high risk for infection or transmission such as in daycare, people a weight cruise, those in nursing homes or perhaps in the military,\” he added. \”Or it may be offered to everyone, since we are exposed previously or any other.\”

Co-authors of the research include Robert L. Atmar and David Y. Graham of the Baylor College of drugs; G. Marshal Lyon, of the Emory University Med school; John J. Treanor, from the University of Rochester Clinic; Wilbur H. Chen from the University of Maryland Med school; Robert W Frenck and Xi Jiang of the Cincinnati Children’s Hospital Clinic; Jan Vinj of the CDC, Mohamed S. AL-Ibrahim of Shin Nippon Biomedical Laboratories; Jill Barrett, of the EMMES Corp.; and Charles Richardson, Robert Goodwin, Astrid Borkowski, Ralf Clemens, and Paul M. Mendelman of Takeda Vaccines.

About The Author